Bookmark This Page | E-mail This Page | Print This Page

Targeting Tumor Cell Proliferation and Promotion of Cell Death: EGFR, HER2, erbB3

Evaluating inhibition of erbB1 (EGFR), erbB2 (HER2), and erbB3 receptor signaling

erbB receptors

Signaling by erbB1 (EGFR), erbB2 (HER2), and erbB3 (HER3) receptors is implicated in the growth, development, and survival of a variety of solid tumors.1,2 Signaling occurs when growth factor ligands bind with erbB receptors causing dimerization, either of 2 receptors of the same type (homodimerization) or of 2 receptors of different types (heterodimerization). This results in activation of the receptor tyrosine kinase.1,2 In some cases erbB receptor activation may occur in the absence of ligand (constitutive activation).1,2

To date, development of agents that specifically target the erbB receptor family has largely focused on either erbB1 or erbB2. However, more complete inhibition of signaling by the erbB receptor family may provide greater antitumor activity.

Targeting Tumor Cell Proliferation & Promotion of Cell Death: EGFR, HER2, erbB3 – AstraZenecaOncology.com

 

Next: Targeting Tumor Cell Proliferation: mTORC1 and mTORC2
     
 

 

References
  1. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal. 2001;2:4-11.
  2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-1174.